NASDAQ:ARTL

Artelo Biosciences Stock News

Healthcare > Biotechnology

Buy ARTL

*Your capital is at risk

$1.46

+0.0100 (+0.690%)

At Close: Jun 03, 2026

Artelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results

04:05pm, Thursday, 14'th May 2026

SOLANA BEACH, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-

Artelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor Development

08:25am, Tuesday, 28'th Apr 2026

SOLANA BEACH, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop trea

Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile

07:50am, Monday, 20'th Apr 2026

Demonstrates ART26.12's Differentiated Profile as a Promising Pain Treatment Ahead of Planned Multiple Ascending Dose Study This Year

Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements

07:50am, Tuesday, 07'th Apr 2026

SOLANA BEACH, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical‑stage pharmaceutical company focused on modulating lipid‑signaling pathways to develop

Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

04:46pm, Monday, 30'th Mar 2026

SOLANA BEACH, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) today announced the closing of its previously announced private placement of 3,188,407 shares of comm

Artelo Biosciences, Inc. (NASDAQ:ARTL) Sees Significant Decrease in Short Interest

02:51am, Saturday, 28'th Mar 2026

Artelo Biosciences, Inc. (NASDAQ: ARTL - Get Free Report) saw a large decline in short interest in the month of March. As of March 13th, there was short interest totaling 37,410 shares, a decline of 2

Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

10:40am, Friday, 27'th Mar 2026

SOLANA BEACH, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) today announced that it has entered into definitive agreements for the purchase and sale of an aggre

Artelo Biosciences Stock Soars After Withdrawing SEC Filing

09:36am, Friday, 27'th Mar 2026

Artelo Biosciences requested the withdrawal of its Registration Statement on Form S-1, initially filed with the U.S. Securities and Exchange Commission on March 20 and declared effective on March 25.

Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments

04:05pm, Wednesday, 25'th Mar 2026

Evaluating Potential to Preserve Muscle Mass Associated with Weight Reduction Announces Preclinical Study Initiation, Patent Filing and Publication of Independent Scientific Research SOLANA BEACH, Cal

Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength

07:31am, Wednesday, 25'th Mar 2026

Three clinical programs, one core molecule, and a capital-efficient strategy position Artelo Biosciences for sustained growth beyond a single indication Three clinical programs, one core molecule, and

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by